Noncoding RNA appears to be involved in the epigenetic regulation of prostate cancer, according to findings published in Nature Genetics.
Mapping the interactions of metastatic prostate tumor gene expression and protein phosphorylation can yield detailed, patient-specific signalling pathway diagrams, and help to identify “master-switch” tumor progression-driving targets for personalized treatment.
Metastatic prostate cancer is more strongly associated than localized disease with germline mutations in DNA repair genes like BRCA1 and BRCA2.
Canadian researchers have tentatively identified urine protein signatures that appear to differentiate aggressive from low-risk prostate tumors.
Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.
A new study published in Nature Communications is suggesting that castration-resistant prostate cancer has particular metabolic characteristics that may open new possibilities for treatment.
Twelve US lawmakers have asked the Obama administration to scrutinize the pricing of the prostate cancer agent enzalutamide and to consider licensing its generic production.
Researchers at UCLA are reporting that prostate adenocarcinoma and neuroendocrine prostate cancer can arise from a common epithelial clone.
A study published in Nature Medicine reports that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds may reduce AR levels in CRPC and stop tumor growth.
Investigators at the University of Washington and the Fred Hutchinson Cancer Research Center are now reporting that a single biopsy may provide enough information to oncologists to guide precision therapy in men with metastatic prostate cancer.